FOLD - רווח לפני ריבית, מסים ופחת Amicus Therapeutics Inc
The EBITDA_Co chart demonstrates a capital reproduction model where the 42.01 level represents the current value. Amicus Therapeutics (FOLD) is implementing automated bioreactors and digital logistics control. High business scalability ensures profit growth through the global distribution of innovations. Key drivers include the commercial success of rare pathology therapies, a strong pipeline, and the expansion of Galafold and Pombiliti drugs.
פילוחי נתונים אנליטיים מרוכזים עבור Amicus Therapeutics, Inc. (FOLD)
The stability of Amicus Therapeutics (FOLD) relies on flawless cold chain logistics for the delivery of orphan drugs, which directly converts into actual cash flow. Tracking EBITDA on the GURU.Markets platform allows for the stripping of accounting write-offs from operating profit, revealing the actual volume of sales proceeds for an objective assessment of the business's fair value.
